HRP20110552T1 - DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE - Google Patents
DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE Download PDFInfo
- Publication number
- HRP20110552T1 HRP20110552T1 HR20110552T HRP20110552T HRP20110552T1 HR P20110552 T1 HRP20110552 T1 HR P20110552T1 HR 20110552 T HR20110552 T HR 20110552T HR P20110552 T HRP20110552 T HR P20110552T HR P20110552 T1 HRP20110552 T1 HR P20110552T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- inhibitor
- prevention
- diseases
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 7
- 125000001399 1,2,3-triazolyl group Chemical class N1N=NC(=C1)* 0.000 title 1
- 108010087894 Fatty acid desaturases Proteins 0.000 title 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- -1 triazole compounds Chemical class 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 201000008980 hyperinsulinism Diseases 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000005623 Carcinogenesis Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021024 Hypolipidaemia Diseases 0.000 claims 2
- 206010023330 Keloid scar Diseases 0.000 claims 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000035508 accumulation Effects 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 230000036952 cancer formation Effects 0.000 claims 2
- 231100000504 carcinogenesis Toxicity 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000006372 lipid accumulation Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- AMDACFIEQFDXOZ-UHFFFAOYSA-N n-[3,5-bis(hydroxymethyl)phenyl]-1-[(3,4-dichlorophenyl)methyl]-5-methyltriazole-4-carboxamide Chemical compound CC1=C(C(=O)NC=2C=C(CO)C=C(CO)C=2)N=NN1CC1=CC=C(Cl)C(Cl)=C1 AMDACFIEQFDXOZ-UHFFFAOYSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 claims 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 230000003228 microsomal effect Effects 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 150000003704 vitamin D3 derivatives Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0722077.5A GB0722077D0 (en) | 2007-11-09 | 2007-11-09 | Compounds |
| PCT/EP2008/065104 WO2009060053A1 (en) | 2007-11-09 | 2008-11-07 | 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110552T1 true HRP20110552T1 (hr) | 2011-09-30 |
Family
ID=38858481
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110552T HRP20110552T1 (hr) | 2007-11-09 | 2011-07-25 | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE |
| HRP20140346AT HRP20140346T1 (hr) | 2007-11-09 | 2014-04-11 | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140346AT HRP20140346T1 (hr) | 2007-11-09 | 2014-04-11 | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8486977B2 (pl) |
| EP (2) | EP2368887B8 (pl) |
| JP (1) | JP5491407B2 (pl) |
| KR (1) | KR101577080B1 (pl) |
| CN (1) | CN101918376B (pl) |
| AT (1) | ATE512140T1 (pl) |
| AU (1) | AU2008324172B2 (pl) |
| BR (1) | BRPI0820471A2 (pl) |
| CA (1) | CA2705113C (pl) |
| CO (1) | CO6270331A2 (pl) |
| CR (1) | CR11482A (pl) |
| CY (2) | CY1112233T1 (pl) |
| DK (2) | DK2368887T3 (pl) |
| DO (1) | DOP2010000137A (pl) |
| EA (1) | EA016621B1 (pl) |
| ES (2) | ES2457521T3 (pl) |
| GB (1) | GB0722077D0 (pl) |
| HK (2) | HK1141528A1 (pl) |
| HR (2) | HRP20110552T1 (pl) |
| IL (1) | IL205152A (pl) |
| MA (1) | MA31801B1 (pl) |
| ME (1) | ME01962B (pl) |
| MX (1) | MX2010005187A (pl) |
| MY (1) | MY163126A (pl) |
| NZ (1) | NZ584725A (pl) |
| PL (2) | PL2368887T3 (pl) |
| PT (2) | PT2207770E (pl) |
| RS (2) | RS53294B (pl) |
| SI (2) | SI2368887T1 (pl) |
| UA (1) | UA107324C2 (pl) |
| WO (1) | WO2009060053A1 (pl) |
| ZA (1) | ZA201002596B (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0722075D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| CN102159605B (zh) * | 2008-09-15 | 2014-01-08 | 大金工业株式会社 | 水性聚合物分散组合物和表面处理剂 |
| NZ592603A (en) * | 2008-10-21 | 2013-02-22 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof |
| FR2974089B1 (fr) * | 2011-04-18 | 2014-04-25 | Univ Nice Sophia Antipolis | Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese. |
| WO2013134546A1 (en) * | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| ES2605632T3 (es) * | 2012-09-17 | 2017-03-15 | F. Hoffmann-La Roche Ag | Derivados triazol carboxamida |
| IL227890A0 (en) * | 2013-08-08 | 2014-01-30 | Galderm Therapeutics Ltd | Antiaging compounds containing bile acid and fatty acid conjugates |
| SI3250563T1 (sl) * | 2015-01-30 | 2022-04-29 | Neurocrine Biosciences, Inc. | Substituirani triazoli in z njimi povezani postopki |
| KR20180036318A (ko) * | 2016-09-30 | 2018-04-09 | 경북대학교 산학협력단 | 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물 |
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| EP3566055A4 (en) | 2017-01-06 | 2020-12-02 | Yumanity Therapeutics, Inc. | TREATMENT METHODS FOR NEUROLOGICAL DISORDERS |
| KR102292989B1 (ko) * | 2017-03-29 | 2021-08-26 | 재단법인 아산사회복지재단 | S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물 |
| EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| WO2019209962A1 (en) * | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| KR102017324B1 (ko) * | 2018-04-30 | 2019-09-02 | 경북대학교 산학협력단 | 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도 |
| CN114656414B (zh) * | 2022-05-24 | 2022-08-23 | 常熟华虞环境科技有限公司 | 三氮唑改性二氧化钛光催化剂及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722941A (en) | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
| US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
| US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
| US5223261A (en) | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
| US20070087363A1 (en) | 1998-12-22 | 2007-04-19 | Myriad Genetics, Incorporated | Therapeutic methods, compounds and compositions |
| ATE475718T1 (de) | 2000-02-24 | 2010-08-15 | Xenon Pharmaceuticals Inc | Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika |
| AU2001289457A1 (en) | 2000-09-26 | 2002-04-08 | Xenon Genetics Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
| TWI265807B (en) * | 2002-04-26 | 2006-11-11 | Lilly Co Eli | Tachykinin receptor antagonists |
| WO2005000821A1 (en) | 2003-06-12 | 2005-01-06 | Eli Lilly And Company | Tachykinin receptor antagonists |
| CA2533901A1 (en) * | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| RU2006105716A (ru) | 2003-07-30 | 2007-09-10 | Зинон Фармасьютиклз Инк. (Ca) | Производные пиридазина и их применение в качестве терапевтических средств |
| WO2007046867A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| WO2007046868A2 (en) | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Thiazolidine derivatives and their uses as therapeutic agents |
| WO2008073461A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
| GB0625605D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625654D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| GB0625604D0 (en) * | 2006-12-21 | 2007-01-31 | Smithkline Beecham Corp | Compounds |
| EP2125799A1 (en) * | 2007-02-28 | 2009-12-02 | Smithkline Beecham Corporation | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
| WO2008138917A1 (en) * | 2007-05-15 | 2008-11-20 | Neurosearch A/S | Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| GB0715055D0 (en) | 2007-08-02 | 2007-09-12 | Smithkline Beecham Corp | Compounds |
| GB0721419D0 (en) | 2007-10-31 | 2007-12-12 | Smithkline Beecham Corp | Compounds |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| GB0722075D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| GB0810913D0 (en) | 2008-06-13 | 2008-07-23 | Smithkline Beecham Corp | Comppounds |
-
2007
- 2007-11-09 GB GBGB0722077.5A patent/GB0722077D0/en not_active Ceased
-
2008
- 2008-07-11 UA UAA201007152A patent/UA107324C2/ru unknown
- 2008-11-07 AU AU2008324172A patent/AU2008324172B2/en not_active Ceased
- 2008-11-07 BR BRPI0820471-3A patent/BRPI0820471A2/pt not_active Application Discontinuation
- 2008-11-07 PT PT08846247T patent/PT2207770E/pt unknown
- 2008-11-07 NZ NZ584725A patent/NZ584725A/en not_active IP Right Cessation
- 2008-11-07 SI SI200831183T patent/SI2368887T1/sl unknown
- 2008-11-07 PL PL11168642T patent/PL2368887T3/pl unknown
- 2008-11-07 JP JP2010532598A patent/JP5491407B2/ja not_active Expired - Fee Related
- 2008-11-07 ES ES11168642.4T patent/ES2457521T3/es active Active
- 2008-11-07 US US12/741,637 patent/US8486977B2/en not_active Expired - Fee Related
- 2008-11-07 ES ES08846247T patent/ES2366422T3/es active Active
- 2008-11-07 EP EP11168642.4A patent/EP2368887B8/en active Active
- 2008-11-07 DK DK11168642.4T patent/DK2368887T3/da active
- 2008-11-07 WO PCT/EP2008/065104 patent/WO2009060053A1/en active Application Filing
- 2008-11-07 EP EP08846247A patent/EP2207770B1/en active Active
- 2008-11-07 MY MYPI2010002145A patent/MY163126A/en unknown
- 2008-11-07 CN CN2008801245066A patent/CN101918376B/zh not_active Expired - Fee Related
- 2008-11-07 PT PT111686424T patent/PT2368887E/pt unknown
- 2008-11-07 RS RS20140219A patent/RS53294B/en unknown
- 2008-11-07 KR KR1020107012597A patent/KR101577080B1/ko active IP Right Grant
- 2008-11-07 DK DK08846247.8T patent/DK2207770T3/da active
- 2008-11-07 ME MEP-2011-369A patent/ME01962B/me unknown
- 2008-11-07 CA CA2705113A patent/CA2705113C/en not_active Expired - Fee Related
- 2008-11-07 RS RS20110369A patent/RS51918B/en unknown
- 2008-11-07 AT AT08846247T patent/ATE512140T1/de active
- 2008-11-07 SI SI200830349T patent/SI2207770T1/sl unknown
- 2008-11-07 EA EA201070588A patent/EA016621B1/ru not_active IP Right Cessation
- 2008-11-07 PL PL08846247T patent/PL2207770T3/pl unknown
- 2008-11-07 MX MX2010005187A patent/MX2010005187A/es active IP Right Grant
-
2010
- 2010-04-14 ZA ZA2010/02596A patent/ZA201002596B/en unknown
- 2010-04-15 IL IL205152A patent/IL205152A/en active IP Right Grant
- 2010-04-30 MA MA32807A patent/MA31801B1/fr unknown
- 2010-05-06 CO CO10054279A patent/CO6270331A2/es active IP Right Grant
- 2010-05-07 DO DO2010000137A patent/DOP2010000137A/es unknown
- 2010-06-09 CR CR11482A patent/CR11482A/es unknown
- 2010-08-20 HK HK10108014.3A patent/HK1141528A1/xx not_active IP Right Cessation
-
2011
- 2011-07-25 HR HR20110552T patent/HRP20110552T1/hr unknown
- 2011-08-26 CY CY20111100816T patent/CY1112233T1/el unknown
-
2012
- 2012-02-02 HK HK12100960.2A patent/HK1160467A1/xx not_active IP Right Cessation
-
2013
- 2013-06-21 US US13/923,420 patent/US9051281B2/en not_active Expired - Fee Related
-
2014
- 2014-04-11 HR HRP20140346AT patent/HRP20140346T1/hr unknown
- 2014-05-09 CY CY20141100328T patent/CY1115058T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110552T1 (hr) | DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE | |
| EP1809601B1 (en) | Compounds for alzheimer's disease | |
| JP4694834B2 (ja) | ８−ヒドロキシキノリン誘導体 | |
| AU2014209387B2 (en) | Toxic aldehyde related diseases and treatment | |
| Saxena et al. | A journey of celecoxib from pain to cancer | |
| JP6783900B2 (ja) | タンパク質凝集の阻害剤としてのヘテロアリールアミド | |
| EA201170193A1 (ru) | Новые содержащие серу липиды для применения в качестве пищевой добавки или в качестве лекарственного средства | |
| CA2851996A1 (en) | Pharmaceutical compositions for substituted quinazolinones | |
| AU2014340182A1 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
| IL167694A (en) | Use of quinazulin-4-on derivatives is used to make derivatives and pharmaceutical preparations containing the derivatives | |
| US7678823B2 (en) | Compounds for alzheimer's disease | |
| RU2010107892A (ru) | Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их | |
| Stoermer et al. | Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds | |
| CN106536500B (zh) | 选择性基质金属蛋白酶抑制剂 | |
| WO2004072041A1 (en) | Tetrahydroquinolines as agonists of liver- x receptors | |
| WO2004072042A2 (en) | Quinoline derivative and their use for modulation of lxr activity | |
| Ramos-Inza et al. | Design, synthesis and anticancer evaluation of novel Se-NSAID hybrid molecules: Identification of a Se-indomethacin analog as a potential therapeutic for breast cancer | |
| AU2015241177B2 (en) | Histone acetyltransferase activators and uses thereof | |
| WO2005092062A2 (en) | Compounds for neurodegenerative disorders | |
| JP2019512475A (ja) | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 | |
| RU2016128529A (ru) | Замещенные бициклические гетероарильные соединения в качестве агонистов rxr | |
| Liu et al. | Novel neuroprotective pyromeconic acid derivatives with concurrent anti-Aβ deposition, anti-inflammatory, and anti-oxidation properties for treatment of Alzheimer's disease | |
| EA016767B1 (ru) | Ретиноидное пролекарственное соединение | |
| JP7378156B2 (ja) | Ｋｅａｐ１／ｎｒｆ２タンパク質間相互作用の１，４－置換イソキノリン阻害剤 | |
| KR20090093807A (ko) | 신경보호효과를 가지는 피루베이트 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |